Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-Methylthiofentanyl is a synthetic opioid analgesic and a structural analog of fentanyl. It acts primarily as an agonist at the mu, delta, and kappa opioid receptors, leading to central nervous system depression with effects such as analgesia (pain relief), euphoria, sedation, and potentially life-threatening respiratory depression. Like other fentanyl analogs, it has a high potential for abuse and overdose. It was briefly sold illicitly in the early 1980s before being classified as a Schedule I controlled substance in the United States due to its lack of accepted medical use and high risk for abuse[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-methylthiofentanyl.